up from here, page-5

Using the $20M for sharebuy back will be the most self-serving purpose for Mr Peter Crook and his board cronies, oops sorry I meant Peter Cook.

As of 1 June 08; there were 181 million shares (excluding Fat options, so $20M is about $0.11 per shares!

Brace yourself for the Relenza sale results out on 23 July.

Tamiflu is no longer the money spinner for Roche and this is how Roche reported the Tamiflu sales today (21 July in Europe. (http://www.roche.com/home/investors/inv_news_upd/inv_news_upd_2008/inv-update-2008-07-21.htm)

Pharmaceuticals
• Sales increase 9%, or more than twice the global market average (excluding Tamiflu pandemic sales).
• Double-digit growth of key products more than outweighs lower Tamiflu pandemic sales; total sales up 3%.


Note how lower Tamiflu sales reduced Roche overall sales increase from 9% to 6%.

Lest we forget, in Nov 2007 Mr Peter Cook said this HOURS before GSK reported a Tsunami drop in Relenza sales:

"There is therefore no reason to assume that the down turn in volumes being experienced by Roche with Tamiflu should be experienced by GSK with Relenza".

Facts are stranger than stories.